With a Darpin antiviral for treating Covid-19 Molecular Partners hopes to follow Vir’s regulatory path.
A win for Vir’s late-to-the-game antibody and another fail for Roche with Actemra show how developers are still feeling their way in Covid-19.
Hopes for the highly valued biotech’s Covid-19 antibody dim before a more important look at the project’s potential.
A trial testing a combination of Lilly and Vir antibodies is the latest attempt by developers to stay ahead of the virus that causes Covid-19.
The company surges 74% though its hints of clinical activity concern just six hep B patients and could include those on placebo.
An NIAID-sponsored study of a Lilly antibody has been paused for possible toxicity, prompting speculation over the cause of the problem.
Lilly’s doublet might be superior to Regeneron’s cocktail, but timing and manufacturing issues could now come into play.